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Polycythemia vera (PV) was first described nearly 120 years ago. In the subsequent cen-
tury, the clinical syndrome of PV, its natural history, its treatment, and many critical patho-
genetic features of the disease were characterized. The discovery of the Janus-associated 
kinase - 2 mutation JAK2 V617F and the characterization of its role in myeloproliferative 
neoplasms have substantially changed the diagnostic paradigm for PV, and have potential 
to lead to new therapy and new pathogenetic insights.
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INTRODUCTION
  Polycythemia vera (PV) is a myeloproliferative neoplasm 
characterized by an absolute erythrocytosis not driven by 
erythropoietin (Epo), i.e., a primary polycythemia. It is dis-
tinguished from other primary polycythemias  by the in-
volvement of other hematopoietic cell lineages [1]. Like other 
myeloproliferative neoplasms, PV is associated with in-
creased risks of evolution to leukemia and of thrombosis 
[2]; like other polycythemia syndromes, many of its signs 
and symptoms result from increased blood viscosity [1].
  Credit for the first description of PV is generally given 
to Henri Vaquez, who in 1892 reported a patient with a 
polycythemia syndrome not due to cardiopulmonary disease 
[3]. He later proposed that erythrocytosis could be divided 
into two syndromes: absolute erythrocytosis or polycythemia, 
resulting from an increased red cell mass; and relative eryth-
rocytosis, resulting from a reduction in plasma volume with-
out increased red cell mass [4]. In 1903, William Osler recog-
nized that several polycythemia cases reported in the liter-
ature or encountered in his extensive consulting practice 
represented a single clinical syndrome not previously de-
lineated, and published a description of this syndrome [5]. 
The Viennese physician Wilhelm Türk subsequently recog-
nized that PV was not solely as disease of the erythron 
but involved other hematopoietic lineages [6], and the basic 
clinical features of PV were largely defined by the time 
Osler wrote a second, shorter review of PV in 1908 [7]. 
The history of the early definition of PV has been reviewed 
in more detail elsewhere [8].
ERA OF CLINICAL/CLINICAL LABORATORY 
DIAGNOSIS
  From its initial descriptions until the last few years, the 
diagnosis of PV has been made by criteria that were based 
upon clinical and clinical laboratory findings. In 1966, the 
U.S. National Cancer Institute funded the Polycythemia Vera 
Study Group (PVSG) to carry out randomized prospective 
trials in PV with the goal of defining the best treatment 
modality [9]. One of the requirements for developing a credi-
ble clinical trials program was the establishment of specific 
criteria for the diagnosis of PV. The subsequent PVSG diag-
nostic criteria (Table 1) were the basis for all PV diagnostic Korean J Hematol 2010;45:90-4.
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Table 1. Diagnostic criteria of the polycythemia vera study group (PVSG).
Criteria Implication for PV diagnosis
M1. Increased Red Cell Mass M1. Identifies actual polycythemia vs. spurious polycythemia
Males: RCM>36/mL/kg; Female: RCM＞32 mL/kg
M2. Arterial O2 saturation＞92% M2. Rules out the most common etiology of secondary polycythemia
M3. Clinical splenomegaly or two of the following: M3. Evidence of a myeloproliferative disorder
m1. Thrombocytosis ＞400,000/ μL
m2. Leukocytosis ＞12,000/ μL
m3. Leukocyte alkaline phosphatase activity ＞100 (no fever or infection)
m4. Serum B12 (＞900 pg/mL) or unsaturated B12 binding capacity (＞2,200 pg/mL)
Adapted from [1]
Table 2. 2001 World Health Organization criteria for the diagnosis
of polycythemia vera major criteria.
A1. Red cell mass  ＞125% of predicted  or  hemoglobin ＞18.5 
g/dL male/16.5 g/dL female
A2. Absence of secondary erythrocytosis
A3. Palpable splenomegaly
A4. Bone marrow endogenous erythroid colony formation
Minor Criteria:
B1. Platelets ＞400,000/μL
B2. Leukocytes ＞12,000/μL
B3. Marrow morphology
B4. Low serum erythropoietin 
Marrow morphology: Hypercellular marrow with trilineage 
hyperplasia; clustering of pleomorphic megakarocytes; absent 
stainable iron: no major inflammatory features.
Requirements for diagnosis:
A1+A2+A3
A1+A2+any two from B
From [17]
schema for 40 years [10].
  The PVSG criteria essentially reflect the need to establish 
three features to make the diagnosis of PV. First, the patient 
must have actual polycythemia and not relative polycythemia 
(M1). Second, it must be shown that the patient does not 
have secondary polycythemia (most commonly due to hypo-
xemia) (M2).  Finally, evidence of a myeloproliferative neo-
plasm needed to be demonstrated (M3 or two minor criteria). 
The PVSG study criteria are based on clinical or clinical 
laboratory parameters, other than the requirement for dem-
onstration of an increased red cell mass by nuclear medicine 
methods. Pathologic parameters (such as bone marrow mor-
phology) were not part of the system, and of course molecular 
diagnostic parameters were not available in 1966.
  Subsequent developments in research on the pathogenesis 
of PV have been incorporated into the basic PVSC criteria 
structure as alternatives or supplements to an original 
criterion. For example, studies of the coefficient of variation 
in red cell mass studies has led to the proposal that a red 
cell mass greater than 125% of predicted value for the local 
laboratory is a more accurate definition than the specific 
red cell mass values included in the original criteria [11]. 
The development of reliable and clinically applicable assays 
for Epo has led to these assays being suggested as a more 
conclusive method to rule out secondary polycythemia [12, 
13]. Alternative major or minor criteria for evidence of a 
myeloproliferative neoplasm include splenomegaly only ap-
parent on radiologic studies [11], demonstration of erythroid 
colony formation in vitro without added Epo (endogenous 
erythroid colonies, or EEC) [14], increased expression of 
the platelet receptor Mpl [15], or of  gene PRV-1 [16]. 
However, these alternatives, as expressed in the 2001 World 
Health Organization (WHO) criteria [17] (Table 2), preserved 
the basic structure and underlying assumptions of the PVSG 
criteria. 
JAK2 V617F IN PV
  In 2005, Kralovics and colleagues reported the results of 
an analysis of the Janus-associated kinase 2 (JAK2) gene 
on chromosome 9 in 244 patients with myeloproliferative 
neoplasms (128 with PV) [18]. They observed a dominant 
gain-of-function mutation in which the valine at position 
617 was replaced by phenylalanine (V617F) in approximately 
half the patients. This mutation appeared to confer an in 
vitro proliferative advantage upon cells into which it was 
transfected [18]. 
  Over the next five years, studies of JAK2 V617F experi-
enced proliferation as well. Mutations of JAK2 V617F were 
reported to occur in 80-96% of cases of PV, and to correlate 
strongly with the 2001 WHO criteria [19-21]. Studies of 
PV patients lacking JAK2 V617F reported that a significant 
number of these had mutations in exon 12 of the JAK2 
gene resulting in a myeloproliferative phenotype, although 
there was some suggestion that exon 12 mutations were 
more likely to be associated with a picture of pure eryth-
rocytosis [22-26]. Unlike the BCR/ABL mutation in chronic 
myelogenous leukemia, JAK2 V617F is not pathognomonic 
for PV but is seen in both essential thrombocytosis (ET) 
and myelofibrosis [18]. It has been reported that JAK2 V617F  
expression identifies a subset of ET patients who are predis-
posed to thrombosis and evolution to myelofibrosis (i.e., 
more like PV patients) [27, 28]. The allele burden of JAK2 
V617F mutations has also been proposed as a tool to dis-
tinguish ET (low allele burden) from PV (high allele burden) Korean J Hematol 2010;45:90-4.
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Table 3. 2008 World Health Organization criteria for the diagnosis 
of polycythemia vera.
Major criteria:
A1. Hemoglobin ＞18.5 g/dL male/16.5 g/dL female; or other 
evidence of increased red cell mass.
A2. Presence of JAK2V617F or other functionally similar mutation
Minor Criteria:
B1. Marrow morphology
B2. Low serum erythropoietin 
B3. Bone marrow endogenous erythroid colony formation
Marrow morphology: Hyper cellular marrow with trilineage hyper-
plasia; clustering of pleomorphic megakarocytes; absent 
stainable iron: no major inflammatory features.
Requirements for diagnosis:
A1+A2+any one from B
A1+any two from B
From [43]
[29]. The JAK2 V617F allele burden is also associated with 
response to hydroxyurea, with a high allele burden predicting 
responsiveness [30], and a reduction in allele burden correlat-
ing with clinical response to hydroxyurea [31].
  In addition to its role in clinical PV, the identification 
of JAK2 V617F has had implications for the understanding 
of the pathogenesis of PV. Transplantation of mice with 
JAK2 V617F expressing cells leads to a myeloproliferative 
neoplasm resembling PV [32, 33]. JAK2 V617F appears to 
be required for the characteristic Epo hypersensitivity of 
PV erythroid progenitors [34]. However, acquisition of JAK2 
mutations does not appear to be the initial molecular event 
in the pathogenesis of PV, but is rather downstream from 
some as yet undetermined initiating event [35, 36].
JAK2 V617F IN PV THERAPY
  As noted above, JAK2 mutation status can serve as a pre-
dictor of response to treatment with hydroxyurea [30], and 
changes in  JAK2 V617F status are associated with response 
to either hydroxyurea or interferon [31, 37]. Reports of agents 
targeted to JAK2 in PV are largely limited to studies using 
various PV model systems [38-40] or to clinical trials in 
post-PV myelofibrosis [41, 42]. The variable results found 
in the reported clinical studies may be either agent-specific 
or specific to the patient subset selected for the study.
JAK2 V617F AND THE ERA OF 
PATHOLOGIC/MOLECULAR DIAGNOSIS
  As discussed earlier, JAK2 V617F is not pathognomonic 
of PV but rather is a hallmark of BCR/ABL-negative myelo-
proliferative neoplasms. Therefore, if it was to be in-
corporated in a diagnostic schematic analogous to the PVSG 
criteria, it would be an alternative to M3, which indicates 
a myeloproliferative neoplasm.
  However, the 2008 modification of the WHO diagnostic 
criteria for PV [43] (Table 3) departed substantially from 
the underlying concepts of the PVSG criteria. The first major 
criterion (A1) remains the demonstration of an increased 
red cell mass, but employs a widely, though not universally 
[44], accepted criterion based on hemoglobin concentration. 
The diagnosis of PV is then made by the finding of two 
additional criteria. This requirement can be met by demon-
strating any two of the following: a low serum Epo concen-
tration, a characteristic bone marrow morphology, the pres-
ence of EEC, or JAK2 V617F (or a functionally similar muta-
tion, like JAK2  exon 12). This departs substantially from 
a reliance on readily available clinical and clinical laboratory 
parameters to more complex testing. PV has become less 
a clinical diagnosis and more a pathologic and molecular 
diagnosis.
HOW IS JAK2 V617F USED IN ACTUAL PRACTICE?
  JAK2 testing has been suggested as the initial step in the 
evaluation of erythrocytosis [45]; however, there is no study 
describing how the general population of hematologists uses 
this test which could be compared to the report by Strieff 
et al. in 2002, which describes the diagnostic and manage-
ment practices prevalent in the early post-PVSG era [46]. 
In a recent report, the use of JAK2 V617F in a single academic 
practice was described [47]. Patients newly presenting with 
a diagnosis of PV were routinely tested for the mutation. 
Of established patients, patients who did not meet the 2001 
WHO diagnostic criteria fully tended to be more likely to 
be tested for JAK2 V617F mutation; patients who seemed 
to have a clearly established diagnosis.
CONCLUSION
  The discovery of the JAK2 V617F mutation, the definition 
of its frequency in PV and other myeloproliferative neo-
plasms, and the identification of its pathophysiologic im-
plications, have transformed the diagnostic approach to PV 
from one based in the clinic and clinical laboratory to a 
truly molecular paradigm. JAK2 V617F has the potential 
to guide therapy of PV and other BCR/ABL-negative myelo-
proliferative neoplasms, whether as a therapeutic target or 
as a marker of response to therapy or of progression risk.
REFERENCES
1. Means RT. Polycythemia vera. In: Greer JP, Foerster J, Rodgers 
GM, et al, eds. Wintrobe's Clinical Hematology. Baltimore, USA: 
Lippincott Williams & Wilkins, 2009:2031-44.
2. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natu-
ral history of 1213 patients followed for 20 years. Ann Intern Med Korean J Hematol 2010;45:90-4.
JAK2 V617F and polycythemia vera 93
1995;123:656-64.
3. Vaquez H. Sur une forme speciale de cyanose s'accompanant d'hy-
perglobulie excessive et persistante. CR Soc Biol (Paris) 1892; 
4:384.
4. Vaquez H, Quiserne P. Des polyglobulies. CR Soc Biol (Paris)  
1902;12:915.
5. Osler W. Chronic cyanosis with polycythemia and enlarged 
spleen: a new clinical entity. Am J Med Sci 1903;126:187-201.
6. Türk W. Beiträge zur Kenntnis des symptomenbildes Polyzythä-
mie mit Milztumor und Zyanose. Wien Med Wochenschr 
1904;17:153-60.
7. Osler W. Erythremia (polycythemia with cyanosis, Maladie de 
Vaquez). Lancet 1908;1:143-6.
8. Means RT Jr. Perspective: Osler's 1903 paper on polycythemia 
vera. Am J Med Sci 2008;335:418-9.
9. Berlin NI, Wasserman LR. Polycythemia vera: a retrospective and 
reprise. J Lab Clin Med 1997;130:365-73.
10. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, 
Wasserman LR. Therapeutic recommendations in polycythemia 
vera based on Polycythemia Vera Study Group protocols. Semin 
Hematol 1986;23:132-43.
11. Pearson TC. Evaluation of diagnostic criteria in polycythemia 
vera. Semin Hematol 2001;38(1 Suppl 2):21-4.
12. Cotes PM, Doré CJ, Yin JA, et al. Determination of serum im-
munoreactive erythropoietin in the investigation of erythro-
cytosis. N Engl J Med 1986;315:283-7.
13. Birgegård G, Wide L. Serum erythropoietin in the diagnosis of pol-
ycythaemia and after phlebotomy treatment. Br J Haematol 
1992;81:603-6.
14. Casadevall N, Vainchenker W, Lacombe C, et al. Erythroid pro-
genitors in polycythemia vera: demonstration of their hyper-
sensitivity to erythropoietin using serum free cultures. Blood 
1982;59:447-51.
15. Moliterno AR, Spivak JL. Posttranslational processing of the 
thrombopoietin receptor is impaired in polycythemia vera. Blood 
1999;94:2555-61.
16. Bock O, Serinsöz E, Neusch M, Schlué J, Kreipe H. The poly-
cythaemia rubra vera-1 gene is constitutively expressed by bone 
marrow cells and does not discriminate polycythaemia vera from 
reactive and other chronic myeloproliferative disorders. Br J 
Haematol 2003;123:472-4.
17. Michiels JJ, De Raeve H, Berneman Z, et al. The 2001 World Health 
Organization and updated European clinical and pathological cri-
teria for the diagnosis, classification, and staging of the 
Philadelphia chromosome-negative chronic myeloproliferative 
disorders. Semin Thromb Hemost 2006;32(4 Pt 2):307-40.
18. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mu-
tation of JAK2 in myeloproliferative disorders. N Engl J Med 
2005;352:1779-90.
19. Ganly P, Hanrahan V, Baker B, Romeril K. Identification of 
JAK2V617F in patients with polycythemia is highly correlated 
with conventional criteria for diagnosis of polycythemia vera. Am 
J Hematol 2007;82:80-2.
20. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 
V617F mutation in chronic myeloproliferative disorders. Blood 
2005;106:2162-8.
21. Verstovsek S, Silver RT, Cross NC, Tefferi A. JAK2V617F muta-
tional frequency in polycythemia vera: 100%, ＞90%, less? 
Leukemia 2006;20:2067.
22. Scott LM, Beer PA, Bench AJ, Erber WN, Green AR. Prevalance 
of JAK2 V617F and exon 12 mutations in polycythaemia vera. Br 
J Haematol 2007;139:511-2.
23. Bernardi M, Ruggeri M, Albiero E, Madeo D, Rodeghiero F. 
Isolated erythrocytosis in V617F negative patients with JAK2 
exon 12 mutations: report of a new mutation. Am J Hematol 
2009;84:258-60.
24. Kouroupi E, Zoi K, Parquet N, et al. Mutations in exon 12 of JAK2 
are mainly found in JAK2 V617F-negative polycythaemia vera 
patients. Br J Haematol 2008;142:676-9.
25. Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence 
and clinicopathologic correlates of JAK2 exon 12 mutations in 
JAK2 V617F-negative polycythemia vera. Leukemia 2007;21: 
1960-3.
26. Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 
in patients with JAK2 (V617F)-negative myeloproliferative 
disorders. Blood 2008;111:1686-9.
27. Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C. The 
presence of the JAK2 V617F mutation is associated with a higher 
haemoglobin and increased risk of thrombosis in essential 
thrombocythaemia. Br J Haematol 2006;132:244-5.
28. Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2 mutation in 
essential thrombocythaemia: clinical associations and long-term 
prognostic relevance. Br J Haematol 2005;131:208-13.
29. Hussein K, Bock O, Theophile K, et al. JAK2(V617F) allele burden 
discriminates essential thrombocythemia from a subset of prefi-
brotic-stage primary myelofibrosis. Exp Hematol 2009;37:1186- 
93.
30. Sirhan S, Lasho TL, Hanson CA, Mesa RA, Pardanani A, Tefferi 
A. The presence of JAK2V617F in primary myelofibrosis or its al-
lele burden in polycythemia vera predicts chemosensitivity to 
hydroxyurea. Am J Hematol 2008;83:363-5.
31. Girodon F, Schaeffer C, Cleyrat C, et al. Frequent reduction or ab-
sence of detection of the JAK2-mutated clone in JAK2V617F-pos-
itive patients within the first years of hydroxyurea therapy. 
Haematologica 2008;93:1723-7.
32. Xing S, Wanting TH, Zhao W, et al. Transgenic expression of 
JAK2V617F causes myeloproliferative disorders in mice. Blood 
2008;111:5109-17.
33. Bumm TG, Elsea C, Corbin AS, et al. Characterization of murine 
JAK2V617F-positive myeloproliferative disease. Cancer Res 
2006;66:11156-65.
34. Dupont S, Massé A, James C, et al. The JAK2 617V＞F mutation 
triggers erythropoietin hypersensitivity and terminal erythroid 
amplification in primary cells from patients with polycythemia 
vera. Blood 2007;110:1013-21.
35. Kralovics R, Teo SS, Li S, et al. Acquisition of the V617F mutation 
of JAK2 is a late genetic event in a subset of patients with myelopro-
liferative disorders. Blood 2006;108:1377-80.
36. Nussenzveig RH, Swierczek SI, Jelinek J, et al. Polycythemia vera 
is not initiated by JAK2V617F mutation. Exp Hematol 2007;35: 
32-8.
37. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interfer-
on-alfa-2a induces complete hematologic and molecular re-
sponses with low toxicity in polycythemia vera. Blood 2008;112: Korean J Hematol 2010;45:90-4.
94 Robert T. Means, Jr. 
3065-72.
38. Pardanani A, Hood J, Lasho T, et al. TG101209, a small molecule 
JAK2-selective kinase inhibitor potently inhibits myeloprolifer-
ative disorder-associated JAK2V617F and MPLW515L/K muta-
tions. Leukemia 2007;21:1658-68.
39. Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A. 
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of 
kinase selectivity and preclinical studies using cell lines and pri-
mary cells from polycythemia vera patients. Leukemia 2009;23: 
1441-5.
40. Gozgit JM, Bebernitz G, Patil P, et al. Effects of the JAK2 inhibitor, 
AZ960, on Pim/BAD/BCL-xL survival signaling in the human 
JAK2 V617F cell line SET-2. J Biol Chem 2008;283:32334-43.
41. Santos FP, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, 
an orally available JAK2 inhibitor, in patients with primary or 
post-polycythemia vera/essential thrombocythemia myelofi-
brosis. Blood 2010;115:1131-6.
42. Hitoshi Y, Lin N, Payan DG, Markovtsov V. The current status and 
the future of JAK2 inhibitors for the treatment of myeloprolifer-
ative diseases. Int J Hematol 2010;91:189-200.
43. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for re-
vision of the World Health Organization diagnostic criteria for 
polycythemia vera, essential thrombocythemia, and primary 
myelofibrosis: recommendations from an ad hoc international ex-
pert panel. Blood 2007;110:1092-7.
44. Johansson PL, Safai-Kutti S, Kutti J. An elevated venous haemo-
globin concentration cannot be used as a surrogate marker for ab-
solute erythrocytosis: a study of patients with polycythaemia vera 
and apparent polycythaemia. Br J Haematol 2005;129:701-5.
45. James C, Delhommeau F, Marzac C, et al. Detection of JAK2 V617F 
as a first intention diagnostic test for erythrocytosis. Leukemia 
2006;20:350-3.
46. Streiff MB, Smith B, Spivak JL. The diagnosis and management of 
polycythemia vera in the era since the Polycythemia Vera Study 
Group: a survey of American Society of Hematology members' 
practice patterns. Blood 2002;99:1144-9.
47. Means RT Jr. JAK2 V617F mutation testing in polycythemia vera: 
use and impact in an academic practice. Am J Med Sci 2008; 
336:327-9.